Anti-Mullerian Hormone in the Female Participants of the Multi-Center Study of Hydroxyurea

项目总结 在美国，患有镰状细胞性贫血(SCA)的患者现在可以存活到成年，使其具有生殖能力 对这群人来说，担忧日益重要。关于SCA如何影响女性的 生殖能力。卵巢可能是氧化和缺氧损伤的终末器官之一- SCA缺血性损伤。羟基脲，一种化疗药物，早在9个月前就开始用于治疗SCA 年龄，也可能影响生育能力。在方法上还没有进行严格的研究，以确定 患有SCA的妇女由于基线SCA或由于 SCA的治疗。这方面的知识尤其重要，因为生育问题是SCA的障碍 治疗，因为有生育力评估和保存战略，但在 患有SCA的女性缺席。这项研究建议测量反苗勒氏激素，一种已建立的 卵巢储备的生物标记物，在羟基尿素多中心研究的样本中，随机 羟基脲治疗成人SCA的安慰剂对照试验。抗苗勒氏症的激素水平将在 羟基脲和安慰剂治疗的受试者，以及在安慰剂治疗组中，临床 将分析具有抗苗勒氏激素水平的特征。来自这个表型良好的队列的样本 为研究未经处理的SCA和羟基尿素如何影响卵巢储备的标志物提供了机会 患有SCA的女性。另一项羟基脲在成人SCA中的安慰剂对照试验将永远不会进行。 因此，这项研究将成为女性生育标志前瞻性研究的跳板。 SCA。 1

PROJECT SUMMARY In the United States, patients with sickle cell anemia (SCA) now survive into adulthood, making reproductive concerns increasingly important for this population. Little is known about how SCA affects women’s reproductive capacity. The ovaries may be among the end-organs injured by the oxidative and hypoxic- ischemic injury of SCA. Hydroxyurea, a chemotherapeutic used to treat SCA starting as early as 9 months of age, may also affect fertility. Methodologically rigorous studies have not yet been performed to identify whether women with SCA have compromised fertility as a consequence of baseline SCA or as a consequence of treatments for SCA. This knowledge is especially important because fertility concerns are a barrier to SCA treatment, and because fertility evaluation and preservation strategies exist, but indications for their use in women with SCA are absent. This study proposes measuring anti-mullerian hormone, an established biomarker of ovarian reserve, in samples from the Multi-Center Study of Hydroxyurea, the randomized placebo-controlled trial of hydroxyurea in adults with SCA. Anti-mullerian hormone levels will be compared in hydroxyurea and placebo treated subjects and within the placebo-treated group, the association of clinical characteristics with anti-mullerian hormone levels will be analyzed. Samples from this well phenotyped cohort provide an opportunity to study how untreated SCA and hydroxyurea may affect a marker of ovarian reserve in women with SCA. Another placebo-controlled trial of hydroxyurea in adults with SCA will never be performed. Thus, this research will serve as a springboard for prospective research on fertility markers in females with SCA. 1